Bicycle Therapeutics, a Phase 1 biotech developing novel oncology medicines based on bicyclic peptides, filed on Friday with the SEC to raise up to $86 million in an initial public offering.
The Cambridge, United Kingdom-based company was founded in 2009 and booked $7 million in sales for the 12 months ended December 31, 2018. It plans to list on the Nasdaq under the symbol BCYC. Bicycle Therapeutics filed confidentially on December 21, 2018. Goldman Sachs, Jefferies and Piper Jaffray are the joint bookrunners on the deal. No pricing terms were disclosed.
